AXS-05

Axsome Therapeutics Inc (NASDAQ: AXSM), which was a high-flier for most of 2019, has come off the all-time highs reached late last year thanks to the COVID-19 pandemic and a negative readout in late March. Positive Phase 2/3 data released by the company Monday morning seems to have...

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) — which skyrocketed 3,565% in 2019 thanks to a steady stream of positive clinical updates — were tanking Monday. Axsome's Mixed Results Trigger Investor Pullback In a late-stage clinical readout, New York-based Axsome...

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM), the best-performing biotech of the year, were ripping higher Monday following a positive clinical readout. Axsome Evaluating Candidate In 4 Indications A Phase 3 study dubbed GEMINI that evaluated Axsome's AXS-05 — an oral...

Axsome Therapeutics Inc (NASDAQ: AXSM) has been a standout performer among biotech stocks year-to-date. From $2.50 at the start of the year, shares now trade above the $18 level. What Happened Axsome announced Monday that the FDA granted Breakthrough Therapy Designation for its AXS-05, which...

Axsome Therapeutics Inc (NASDAQ: AXSM) shares, which were trading at sub-$3 levels before the start of the year, have soared to the mid-teens. The stock has gained about 400 percent year-to-date.  After a roller coaster ride over the past two sessions, Axsome shares were advancing strongly...

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) and SAGE Therapeutics Inc (NASDAQ: SAGE) were moving sharply higher Monday on separate clinical trial results.  Axsome's Major Depressive Disorder Drug Trial Axsome said its lead pipeline asset AXS-05 met its primary endpoint of...

Biotechs Axsome Therapeutics Inc (NASDAQ: AXSM) and Axovant Sciences Ltd (NASDAQ: AXON) were taking diverging paths Monday.  While shares of Axsome surged higher by nearly 8 percent, Axovant shares were down by more than 25 percent at the time of publication.  Positive Interim Results...